Alejandro Rios Hoyo
Associate Research ScientistCards
About
Research
Publications
2024
Evaluation of large language models as a diagnostic aid for complex medical cases
Ríos-Hoyo A, Shan N, Li A, Pearson A, Pusztai L, Howard F. Evaluation of large language models as a diagnostic aid for complex medical cases. Frontiers In Medicine 2024, 11: 1380148. PMID: 38966538, PMCID: PMC11222590, DOI: 10.3389/fmed.2024.1380148.Peer-Reviewed Original ResearchClinical casesLanguage modelHospital case recordsConsecutive clinical casesDifferential diagnosis listComplex clinical casesDifferential diagnosisDiagnostic considerationsCase discussionDiagnostic aidCase recordsDiagnosisComplex medical casesDiagnosis listDifferential listMedical specialtiesMedical professionalsDiseaseIncidenceCorrelation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.
Rios-Hoyo A, Xiong K, Marczyk M, García-Millán R, Wolf D, Huppert L, Nanda R, Yau C, Hirst G, van 't Veer L, Esserman L, Pusztai L. Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial. Journal Of Clinical Oncology 2024, 42: 573-573. DOI: 10.1200/jco.2024.42.16_suppl.573.Peer-Reviewed Original ResearchGene expression dataGene expression analysisExpression dataExpressed genesExpression analysisTriple-negativeDistance analysisPathway analysisDifferential gene expression analysisCell cycle pathwayGene set enrichment analysisBreast cancerIngenuity Pathway AnalysisRate of pathological complete responseHigh-risk stage IIGlucocorticoid receptor signalingTriple negative breast cancerCycle pathwayPathological complete responseDNA repairEnrichment analysisOptimal treatment strategyNegative breast cancerI-SPY2 trialGenesUnveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo A, Monzonís X, Vidal J, Linares J, Montagut C. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Frontiers In Pharmacology 2024, 15: 1398419. PMID: 38711991, PMCID: PMC11070789, DOI: 10.3389/fphar.2024.1398419.Peer-Reviewed Original ResearchAnti-EGFR therapyResistance to anti-EGFR therapySecondary resistance to anti-EGFR therapiesColorectal cancerEmergence of acquired resistanceExtracellular domain of EGFRMetastatic colorectal cancerBlood of patientsClinical cohort studyDomain of EGFRMulti-drug treatmentBenefits of rechallengeEGFR blockadePotential therapeutic strategyAnti-EGFRClinical benefitTumor cellsGenomic alterationsLiquid biopsyCohort studyClinical trialsTherapeutic strategiesTherapyPatientsRechallengeNeoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
Ríos-Hoyo A, Cobain E, Huppert L, Beitsch P, Buchholz T, Esserman L, van 't Veer L, Rugo H, Pusztai L. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer. Journal Of Clinical Oncology 2024, 42: 2632-2636. PMID: 38593393, DOI: 10.1200/jco.23.02614.Peer-Reviewed Original Research
2023
Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic
Rios-Hoyo A, Arriola E. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic. Frontiers In Immunology 2023, 14: 1221097. PMID: 37876939, PMCID: PMC10590916, DOI: 10.3389/fimmu.2023.1221097.Peer-Reviewed Original ResearchConceptsBrain metastasesCell lung cancerLung cancerTumor cellsTreatment strategiesAnti-CTLA-4 antibodyManagement of brain metastasesPD-1/PD-L1 axisNon-small cell lung cancerSmall cell lung cancerBrain parenchymaEra of immunotherapyIntracranial malignant neoplasmsSequence of immunotherapySymptomatic brain metastasesImmune checkpoint inhibitorsPD-1/PD-L1Extravasation of tumor cellsTreatment of BMBlood-brain barrierCheckpoint inhibitorsDismal prognosisImmune cellsLocal invasionProtumor effects14P Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Campos M, Hardy-Werbin M, Gibert J, Ríos-Hoyo A, Rossell A, Gonzalez S, Rocha P, Del Rey-Vergara R, Rovira A, Arriola E. 14P Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy. Annals Of Oncology 2023, 34: s191. DOI: 10.1016/j.annonc.2023.09.1517.Peer-Reviewed Original ResearchAssociations amongst genes, molecules, cells, and organs in breast cancer metastasis
Nathanson S, Dieterich L, Zhang X, Chitale D, Pusztai L, Reynaud E, Wu Y, Ríos-Hoyo A. Associations amongst genes, molecules, cells, and organs in breast cancer metastasis. Clinical & Experimental Metastasis 2023, 1-21. PMID: 37688650, DOI: 10.1007/s10585-023-10230-w.Peer-Reviewed Original ResearchBreast cancer metastasisBreast cancerCancer metastasisOutcomes of patientsAnti-tumor immunityHope of cureAggressive therapyMultiple metastasesAggressive treatmentBone metastasesLymph nodesSystemic metastasesMorphologic subtypesClinical oncologistsMetastasisInternal visceraAssists cliniciansLymphatic endothelial cellsPatientsEndothelial cellsHealth SymposiumBasic scientistsMolecular expressionCancerMolecular aspects
2022
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. British Journal Of Cancer 2022, 128: 21-29. PMID: 36289372, PMCID: PMC9814154, DOI: 10.1038/s41416-022-01991-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalPhase Ib studyDNA damage repairOverall survivalSafety profileMedian radiographic progression-free survivalMetastatic castration-resistant prostate cancerOpen-label phase Ib studyIb studyDNA damage repair alterationsRadiographic progression-free survivalPD-1/PD-L1 inhibitorsCastration-resistant prostate cancerTreatment-related adverse eventsMedian response durationAndrogen receptor inhibitorsMedian OSSipuleucel-TProlonged OSPretreated populationSurvival benefitPrimary endpointProstate cancerSecondary endpointsAndrogen receptorEP14.05-002 Impact of Body Mass Index on Survival in Patients with Small Cell Lung Cancer
Rios-Hoyo A, Masfarré L, Navarro-Gorro N, Rocha P, Galindo-Campos M, del Rey Vergara R, Taus Á, Arriola E. EP14.05-002 Impact of Body Mass Index on Survival in Patients with Small Cell Lung Cancer. Journal Of Thoracic Oncology 2022, 17: s543-s544. DOI: 10.1016/j.jtho.2022.07.977.Peer-Reviewed Original ResearchAcquired Mechanisms of Resistance to Osimertinib—The Next Challenge
Ríos-Hoyo A, Moliner L, Arriola E. Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge. Cancers 2022, 14: 1931. PMID: 35454838, PMCID: PMC9027936, DOI: 10.3390/cancers14081931.Peer-Reviewed Original ResearchMechanisms of resistanceNon-small cell lung cancerEGFR-mutant tumorsPercentage of non-small cell lung cancerCell lung cancerMultiple mechanisms of resistanceEGFR tumorsPotential therapeutic strategyClinical benefitToxicity profileTreatment optionsLung cancerFrequent alterationsTherapeutic strategiesAcquired mechanismsOsimertinibTumorMultiple mechanismsTreatmentEGFRIncreased useCancer
Links & Media
News
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- May 31, 2024
2024 ASCO Conquer Cancer Grants & Awards Announced
- November 28, 2023
Yale Cancer Center Experts Present New Research at Leading Breast Cancer Symposium
- February 15, 2023
Celebrating New Faculty, Staff, Postdocs & Postgrads! (February 2023)